2023/4/25更新：Sponsor由康方变成Summit Therapeutics；U.S. FDA-regulated Drug，从No变成YES；增加OS作为双终点；招募标准仍然是“Have previously received EGFR-TKI treatment and the treatment has failed”；
同年5/23更新：招募标准修改为：Have previously received 3rd generation EGFR-TKI treatment and have progressed on or following；
*****************
国内部分，January 1, 2022就开始入组了。